Posaconazole
Template:Short description Template:Use dmy dates Template:Cs1 config Template:Drugbox
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.[1][2]
It was approved for medical use in the European Union in October 2005,[3] and in the United States in September 2006.[4][5] It is available as a generic medication.[6][7]
Medical uses
Posaconazole is used to treat invasive Aspergillus and Candida infections.[4] It is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to other drugs such as itraconazole and fluconazole.[4]
Clinical evidence of efficacy in treatment of invasive disease caused by Fusarium species (fusariosis) is limited.[8]
It appears to be helpful in a mouse model of naegleriasis[9] and kills Acanthamoeba castellanii cysts in vitro.[10]
It has been used to treat mucormycosis (black fungus disease) caused by Rhizopus mold. [11]
Pharmacology
Pharmacodynamics
Posaconazole works by disrupting the close packing of acyl chains of phospholipids, impairing the functions of certain membrane-bound enzyme systems such as ATPase and enzymes of the electron transport system, thus inhibiting growth of the fungi. It does this by blocking the synthesis of ergosterol by inhibiting of the enzyme lanosterol 14α-demethylase and accumulation of methylated sterol precursors. Posaconazole is significantly more potent at inhibiting 14-alpha demethylase than itraconazole.[4][12][13]
Microbiology
Posaconazole is active against the following microorganisms:[12][14]
- Candida spp.
- Aspergillus spp.
- Zygomycetes spp. Script error: No such module "Unsubst".
Pharmacokinetics
Posaconazole is absorbed within three to five hours. It is predominantly eliminated through the liver, and has a half-life of about 35 hours. Oral administration of posaconazole taken with a high-fat meal exceeds 90% bioavailability and increases the concentration by four times compared to fasting state.[4][14]
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".Script error: No such module "Unsubst".Template:Cbignore
- ↑ Cite error: Script error: No such module "Namespace detect".Script error: No such module "Namespace detect".
- ↑ a b c d e Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ a b Brunton L, Lazo J, Parker K. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. San Francisco: McGraw-Hill; 2006. Template:ISBN
- ↑ Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "citation/CS1".
Script error: No such module "Check for unknown parameters".
External links
Script error: No such module "Navbox". Template:Piperazines Template:Portal bar Template:Authority control
- Pages with script errors
- Pages with reference errors
- 1,2,4-Triazol-3-ones
- 27-Hydroxylase inhibitors
- CYP3A4 inhibitors
- Fluoroarenes
- Lanosterol 14α-demethylase inhibitors
- Drugs developed by Merck & Co.
- Orphan drugs
- Piperazines
- Phenylethanolamine ethers
- Drugs developed by Schering-Plough
- Secondary alcohols
- Tetrahydrofurans
- Triazole antifungals
- Ureas
- Antiprotozoal agents